Our investigation in the overall leukemia patient dataset reveals the most frequently observed EZH2 mutations to be R690 and D664 (Table 2), both of which are loss-of-function mutations [68–70]; both are located in the SET domain (catalytic domain) and are directly associated with inactivation of PRC2. Here, EZH2 is linked to leukemia.